Other Research Programs

We are conducting additional research to build on our pioneering RNA-based technology platforms and expand the potential of our research and development efforts.

Additional research programs utilizing AVI’s RNA-based platforms and PMO-X, PMOplus™ and PPMO chemistries are being advanced for certain rare and infectious diseases, and other select opportunities.

The information set forth above is current only as of the dates noted. While we will make reasonable attempts to keep the information current, there is no guarantee that we will be successful and, except as required under applicable federal and state laws, we disclaim any obligation to do so. Readers are invited to visit the press release and SEC documents sections of this website for more up to date information about the Company and its research, development and clinical programs as well as other aspects of its business.

This page was last updated on July 22, 2010.